WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

From Dose to Circulation: Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System

November 22, 2021

Resource > Webinars >

From Dose to Circulation: Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System


Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System

Filed under: ADME and Drug bioavailability

web s4e4 |

Video content if present

From Dose to Circulation

Determination of Drug Oral Bioavailability Using a Gut-Liver Microphysiological System


Watch this webinar to learn:

  • Learn how bioavailability can be determined in vitro using human cells
  • Discover how gut-liver MPS can be used to evaluate a key ADME parameter
  • Discuss the application of mathematical modeling to predict oral bioavailability

In this webinar, Dr. Yassen Abbas discusses how CN Bio’s gut-liver MPS can be used for in vitro determination of oral bioavailability. This application has been validated with drugs with known human bioavailability and with a mathematical model developed to enable prediction of oral bioavailability in silico.

Bioavailability is a key parameter of a drug’s behaviour and is determined during pre-clinical development. It is the fraction of a compound that reaches systemic circulation and is important for efficacy and safety considerations. Bioavailability estimations to date have relied heavily on animal models. However, these models are expensive and have limited relevance to humans.


View our Q&A document from the live event.


Speaker Information:

yassDr Yassen Abbas

Senior Scientist
CN Bio

Video content if present

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023